DaHui has extensive experience developing and executing market-entry strategies for foreign investors in China. We position our clients not only for successful deployment across various sectors of the Chinese economy, but also for strategic onshore growth and survival in the local market in the long run.
We thoroughly assess our international clients’ business objectives and plans in China, and work with them every step of the way until their goals are realized. We advise our clients, large and small, on issues ranging from major investment projects to day-to-day operations. We are keenly aware of the challenges and risks involved in investing in China’s emerging markets, and pride ourselves in our ability to help our clients navigate the local business environment to achieve their goals. Frequently, our clients engage us from the outset of an investment, where we assist in identifying and vetting potential onshore business partners, choosing locations and conducting any necessary due diligence, prior to entry in China. Following our initial entry work, we remain in close contact with our clients and stay constantly abreast of trends and developments in the local market, always ensuring that our clients are getting the most out of their China business.
Given China’s unique regulatory framework across various sectors of its economy, it is not unusual for newcomers to feel lost or confused, or not sure of where to begin, especially considering the considerable market rumors and competing voices that routinely flood the business/regulatory landscape in China. By relying on our firm’s unique and embedded approach to China’s regulatory environment (particularly in some of China’s most heavily regulated sectors and industries), our firm cuts through the noise and empowers our clients to make informed and strategically structured decisions on how to best participate in the China market, helping to facilitate the growth and likelihood of success of their China operations, long into the future.
Our services in this area include:
Represented Apyx Medical (f.k.a. Bovie Medical), an advanced medical and energy technology company listed on NASDAQ (APYX), in its establishment of a joint venture with a local partner to manufacture, research, develop and sell electrosurgery generators in China.
Advised The BMJ, one of the oldest general medical journals and now an international peer-reviewed and a fully "online first" publication, on numerous corporate structuring matters in China, positioning the company to expand its presence in the China market and help boost the PRC healthcare industry by providing access to The BMJ's various information services.
Assisted CBS with multiple stages of its entrance, expansion and re-alignment in the China market, including matters relating to operating licenses, restructuring and sales of assets, as well as compliance issues related to its local projects and operations.
Advised Cirium (f.k.a. Flight Global), a world-leading data and aviation analytics solution provider, on struturing, licensing and contracts, as well as on regulatory requirements concerning storage, maintenance, trade and publishing of sensitive data, for its expansion in the China market.
Advised Cloudflare on multiple aspects of offering services such as DNS and CDN directly within the restrictive local internet and telecoms sectors, including via tailored structuring of its products and optimal contractual partnership models.
Sep 17, 2021